Reducing Amyloid Plaque Burden with Gene Therapy for Alzheimer's Disease
Author Information
Author(s): Matthew L Hemming, Michaela Patterson, Casper Reske-Nielsen, Ling Lin, Ole Isacson, Dennis J Selkoe
Primary Institution: Brigham and Women's Hospital and Harvard Medical School
Hypothesis
Can ex vivo gene delivery of an Aβ-degrading protease reduce amyloid plaque burden in the brain?
Conclusion
Ex vivo gene delivery of an Aβ-degrading protease reduces amyloid plaque burden in transgenic mice expressing human APP.
Supporting Evidence
- Ex vivo gene delivery resulted in a 72% reduction in plaque burden at the graft site.
- Significant reductions in plaque burden were observed in both the medial and lateral hippocampus.
- The study supports the use of Aβ-degrading proteases as a therapeutic approach for Alzheimer's disease.
Takeaway
Scientists found a way to help mice with Alzheimer's by using special cells to deliver a protein that breaks down harmful brain plaques.
Methodology
The study used ex vivo gene delivery of a secreted form of neprilysin into the brains of APP transgenic mice to assess its effect on amyloid plaque burden.
Limitations
The study did not assess the behavioral effects of the treatment on the mice.
Participant Demographics
Transgenic mice expressing human amyloid precursor protein (APP).
Statistical Information
P-Value
p = 0.0269; p = 0.0020; p = 0.0081
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website